title: Smoking cessation: aspects of prevention and therapy. The activity of the Smoking Cessation Center of Parma-Italy.
abstract: The World Health Organization states that only a reduction in tobacco use would lower the number of deaths from cancer. It is possible to decrease the number of deaths by means of prevention and/or smoking cessation. Smoking cessation therapy includes both psychological support and pharmacological treatment: Nicotine Replacement Therapy (NRT), Bupropion Sustained-Release, and Varenicline. The aim of the Smoking Cessation Center of Parma is to provide instruments, methodologies and individual therapies for achieving abstinence or a decrease in tobacco use. The program of the Smoking Cessation Center consists in eight meetings. During the first meeting the smoker undergoes a medical check up, and smoking history, exhaled single breath CO and dependence of nicotine are recorded and a personal therapy is planned. During each follow-up visit (after 15 days and then at 1,2,3,6,9 and 12-month intervals) the compliance of the patient to the treatment and abstinence symptoms are assessed. Since 2000, we achieved tobacco abstinence in 28% of patients. Combined treatment (Bupropion/NRT) provided a higher percentage of success (39.9%).
authors.affiliation: Department of Clinical Science, Unit of Pulmonary Function, University of Parma, Italy.
authors.forename: Maria Elena
authors.initials: ME
authors.lastname: Mariano
authors.forename: Davide
authors.initials: D
authors.lastname: Elia
authors.forename: Alessandro
authors.initials: A
authors.lastname: Scarascia
authors.forename: Panagiota
authors.initials: P
authors.lastname: Tzani
authors.forename: Giuliano
authors.initials: G
authors.lastname: Giucastro
authors.forename: Dario
authors.initials: D
authors.lastname: Olivieri
authors.forename: Emilio
authors.initials: E
authors.lastname: Marangio
mesh_terms: D000328:Adult; D000554:Ambulatory Care Facilities; D018687:Antidepressive Agents, Second-Generation / Q000008:administration & dosage; D001552:Benzazepines / Q000008:administration & dosage; D016642:Bupropion / Q000008:administration & dosage; D015331:Cohort Studies; D037001:Directive Counseling; D005260:Female; D006801:Humans; D007558:Italy; D008297:Male; D008875:Middle Aged; D018722:Nicotinic Agonists / Q000008:administration & dosage; D010349:Patient Compliance; D011810:Quinoxalines / Q000008:administration & dosage; D012189:Retrospective Studies; D016540:Smoking Cessation / Q000379:methods*; D016896:Treatment Outcome; D000068580:Varenicline
chemical_list: D018687:Antidepressive Agents, Second-Generation; D001552:Benzazepines; D018722:Nicotinic Agonists; D011810:Quinoxalines; D016642:Bupropion; D000068580:Varenicline